Overexpression of miRNA-216 in exosomes derived from umbilical cord mesenchymal stem cells promotes angiogenesis and improves functional recovery after spinal cord injury
Li H., Yi R., Fan Y., Zhan G., Xiao T.
Animal Study on Spinal Cord Injury, published in Iran J Basic Med Sci (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- Iran J Basic Med Sci (2025)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 40896704
- PMCID
- PMC12399067
- DOI
- 10.22038/ijbms.2025.85963.18571
- Citations
- 1
Abstract (original English)
Objectives This study aimed to engineer miR-216-overexpressing umbilical cord mesenchymal stem cells (UCMSCs) to generate miR-216-enriched UCMSC-derived exosomes (UCMSC-Exos) and evaluate their therapeutic potential in Spinal cord injury (SCI). Materials and methods miR-216 overexpression was achieved in UCMSCs, and exosomes were subsequently isolated. The biological effects of miR-216-overexpressing UCMSC-Exos (UCMSC-miR-216 OE -Exos) were assessed using in vitro migration, and tube formation assays with vascular endothelial cells. For in vivo evaluation, SCI mouse models were treated with either UCMSC-Exos or UCMSC-miR-216 OE -Exos. Functional recovery was measured using the BMS scores, while angiogenesis, neuronal apoptosis, and proinflammatory cytokine expression were analyzed through immunohistochemistry and molecular assays. Results qPCR analysis confirmed successful miR-216 overexpression in UCMSCs and their derived exosomes. In vitro , UCMSC-miR-216 OE -Exos significantly enhanced endothelial cell migration and tube formation compared to control UCMSC-Exos. In vivo , both UCMSC-Exos and UCMSC-miR-216 OE -Exos improved BMS scores, promoted angiogenesis, and reduced neuronal apoptosis and proinflammatory cytokine expression in SCI mice. Notably, UCMSC-miR-216 OE -Exos demonstrated superior therapeutic effects, including greater improvements in functional recovery, enhance
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.
Related research
- Level ASystematic ReviewPubMed
Host immune determinants of stromal vascular fraction graft survival: Toward a concept of SVF therapy resistance - A systematic narrative review.
Systematic Review on Spinal Cord Injury, Chronic Inflammation, Immune Modulation, published in Cell Transplant (2026) — summary generated from the PubMed abstract.
- 2026
Cell Transplant - Level AMeta-analysisPubMed
Stem cell-derived exosome treatment for acute spinal cord injury: a systematic review and meta-analysis based on preclinical evidence.
Meta-analysis on Spinal Cord Injury, published in Front Neurol (2025) — summary generated from the PubMed abstract.
- 2025
Front Neurol - Level ASystematic ReviewPubMed
Brain-derived neurotrophic factor (BDNF) as biomarker in stem cell-based therapies of preclinical spinal cord injury models: A systematic review.
Systematic Review on Spinal Cord Injury, published in Tissue Cell (2025) — summary generated from the PubMed abstract.
- 2025
Tissue Cell3 citations - Level ASystematic ReviewEurope PMC
Revolutionizing neural regeneration with smart responsive materials: Current insights and future prospects
Systematic Review on Spinal Cord Injury, published in Bioact Mater (2025) — summary generated from the PubMed abstract.
- 2025
Bioact Mater5 citations - Level ASystematic ReviewEurope PMC
Conductive Nanocomposite Hydrogels for Neural Tissue Engineering: A Systematic Scoping Review of Recent Trends
Systematic Review with a reported sample of 42 on Diabetic Foot, Stroke Research, Spinal Cord Injury, Neuroinflammation, published in Adv Sci (Weinh) (2025) — summary generated from the PubMed abstract.
- 2025
- n = 42
Adv Sci (Weinh)18 citations - Level ASystematic ReviewEurope PMC
Emerging regenerative strategies for spinal cord injury: exosome-derived mechanisms and therapeutic insights
Systematic Review on Spinal Cord Injury, Neuroinflammation, published in Front Neurosci (2025) — summary generated from the PubMed abstract.
- 2025
Front Neurosci